Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Total Liabilities: 2023-2024

Historic Total Liabilities for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $14.8 million.

  • Contineum Therapeutics' Total Liabilities rose 78.73% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year increase of 78.73%. This contributed to the annual value of $14.8 million for FY2024, which is 159.22% up from last year.
  • Per Contineum Therapeutics' latest filing, its Total Liabilities stood at $14.8 million for FY2024, which was up 159.22% from $5.7 million recorded in FY2023.
  • Over the past 5 years, Contineum Therapeutics' Total Liabilities peaked at $14.8 million during FY2024, and registered a low of $5.7 million during FY2023.
  • For the 2-year period, Contineum Therapeutics' Total Liabilities averaged around $10.2 million, with its median value being $10.2 million (2023).
  • Data for Contineum Therapeutics' Total Liabilities shows a peak YoY surged of 159.22% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Contineum Therapeutics' Total Liabilities stood at $5.7 million in 2023, then soared by 159.22% to $14.8 million in 2024.